Strategies to Improve Treatment - Barrett's Esophagus

This content has been reviewed and approved by

Chandra P. Belani, MD
Deputy Director, Penn State Cancer Institute
Miriam Beckner Professor of Medicine
Penn State University School of Medicine
 

Researchers are currently investigating new treatments for Barret's esophagus. Participation in trials of these treatments can lead to improved therapies. If you wish to participate in a clinical trial, please talk to your doctor about the potential benefits and side effects of the treatment.

Reversal therapy - Because Barrett's esophagus and associated dysplastic changes limit themselves to the surface lining of the esophagus, researchers continue to evaluate new methods of reversing these changes.

Below are three methods of burning off the abnormal cells; all methods use an endoscope. These methods are:

  • Electrocoagulation - Uses electricity
  • Heater probe (thermal ablation) - Uses heat
  • Argon plasma coagulation - Uses electrically conducting argon gas

Other strategies include:

  • Photodynamic laser treatment - This treatment involves injecting a drug that is sensitive to light into a vein. The abnormal cells take up this drug. About 48 hours later, the patient returns for upper endoscopy. During the endoscopy, the physician passes a red, non-heat-producing laser light through the endoscope and directs this light onto the abnormal cells. The reaction between the laser and the drug destroys the abnormal cells.
  • Chemoprevention - investigational at present

It is necessary to conduct more long-term studies to know whether any of these treatments can prevent cancer from developing.

This content was last modified on November 16, 2007 .
Latest Cancer News
Campath® and Rituxan® Promising for Untreated High-risk CLL

October 7, 2008 — Researchers from the Mayo Clinic have reported that early treatment of asymptomatic patients with high-risk features of chronic lymphocytic leukemia (CLL) with Campath® (alemtuzumab) and Rituxan® (rituximab) appears promising. The details of this study appeared in the October 15, 2008 issue of Cancer.

Long-term Incense Use Increases Risk of Cancer Upper Respiratory Tract Cancer

October 7, 2008 — Researchers from Singapore have reported that long-term incense use increases the risk of squamous cell carcinoma of the respiratory tract. The details of this study appeared in the October 1, 2008 issue of Cancer.

Arimidex® Not Associated with Cognitive Impairment Among Postmenopausal Women at High Risk for Breast Cancer

October 7, 2008 — The use of the aromatase inhibitor Arimidex® (anastrozole) does not appear to be associated with cognitive impairment among postmenopausal women at a high risk of developing breast cancer. These results were recently published in the Lancet Oncology.

Select news items provided by Reuters Health